

Appendix 2: CBC Phase 1 Planning permissions

Floorspace Type (Square metres)	Biomedical and Biotech R&D (B1(b))	Clinical research and treatment (D1 and/or clinical in-patient treatment)	Clinical research and treatment (D1 and/or clinical in-patient treatment) OR Higher Education OR Sui generis medical research institute uses	Biomedical and Biotech R&D (B1(b)) OR Clinical research and treatment (D1 and/or clinical in-patient treatment)	Total
Outline permission (06/0796/OUT)	115,000	60,000	25,000	15,000	215,000
LMB Building (07/0651/FUL)	25,209	-	-	-	25,209
New Papworth Hospital (14/1411/REM)	-	-	18,300	15,000	33,300
AstraZeneca (14/1633/REM)	59,821	-	-	-	59,821
AstraZeneca Phase 2 committed	20,884	-	-	-	20,884
Plot 8 Bellatrix (16/0653/REM) <i>Pending</i>	9,033	-	-	-	9,033
Plot 9 (16/1078/OUT) <i>Pending</i>	14,193	-	-	-	14,193

Total Detailed Floorspace Approved	85,030	0	18,300	15,000	118,330
Total Pending	44,110	0	0	0	9,033
Total committed	129,140				
Total remaining	0	60,000	6,700	0	87,637